Open label noninferiority RCT "METOGiA" in GCA TCZ improved relapse free survival (83% vs 67% MTX) & pred free remission (81% vs 61% MTX) wk 52. Ignore the weird primary endpt at week 78 Everyone also got pred; are we sure MTX works at all? @RheumNow #ACR25 #ACRBest Abstr#0891 https://t.co/i48JBnawB7

• https://x.com/EBRheum/status/1982824859936669713/photo/1
• https://x.com/EBRheum/status/1982824859936669713/photo/1

A randomized trial of app-based behavioral (acceptance and commitment) therapy (ACT) showed reduced pain interference and affective distress in axial SpA compared to standard of care. Acceptance was moderate, but impact was meaningful. Abstract 1461 @RheumNow #ACR25 https://t.co/sF5Ldtc61R

• https://x.com/synovialjoints/status/1982824618147680733/photo/1

#1077 More health literacy work from our group! 995 people with inflammatory arthritis: lower health literacy linked to higher absenteeism & presenteeism Those with highest HLQ scores were mostly retired with better engagement in care @RheumNow #ACR25 Come check out our poster! https://t.co/CaqzkjMWYB

• https://x.com/DrMiniDey/status/1982824613466808365/photo/1

#ACR25 Abstr#1526 Finally it’s here! Consensus-based guidance on GC #steroid tapering in patients with #SLE. Included considerations before tapering, tapering schedules and monitoring during tapering. Looking forward to the uptake and hearing patients’ views @RheumNow #ACRBest https://t.co/FFl2TFhtTa

• https://x.com/Yuz6Yusof/status/1982823893199880429/photo/1

REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/CLmCdBXiOf https://t.co/z20nWd2NSM

• REPLENISH - Secukinumab Works in Polymyalgia Rheumatica | RheumNow

#0850 Single-cell RNA-seq of RA synovium uncovers a new biomarker & therapeutic target: PHIF Made by Tph cells, drives macrophage activation and mirrors disease severity. Big step forward in understanding RA immunopathogenesis. @RheumNow #ACR25 https://t.co/KtyxU0Lqly

• https://x.com/DrMiniDey/status/1982801203584201214/photo/1

This retrospective study evaluated incidence of MACE & mortality among PsA pts on GLP-1RAs vs non-GLP-1RAs After propensity score matching, pts on GLP-1RAs = ⬇️ risk of developing MACE & ⬇️ mortality vs. non GLP-1RAs Interesting data, More research reqd #ACR25 @RheumNow Abs0849 https://t.co/hiPpQH0K3O

• https://x.com/RHEUMarampa/status/1982802974314254418/photo/1
• https://x.com/RHEUMarampa/status/1982802974314254418/photo/1

TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls Without much surprise GLP-1 treated pts had lower risk of MACE and death Observational, retrospective study. Now awaiting the prospective evidence. RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK

• https://x.com/AurelieRheumo/status/1982803333078225298/photo/1

Next Generation T-Cell Engager: The Future https://t.co/gcrfzV6MSJ via @YouTube @alhkim great to see you and hearing all about new T cell Engager , feasibility and less toxicity. @RheumNow #ACR25

• Next Generation T-Cell Engager: The Future

#0851 Urinary Tenascin C predicts kidney function loss in lupus nephritis 170 AMP-LN patients: Tenascin C (from renal myofibroblasts) was the top predictor of eGFR decline (HR 4.6) Proteomic 11-marker risk score (AUC 0.91) outperformed proteinuria for prognosis #ACR25 @RheumNow

In the #ACR25 Great AI debate, @RADoctor shows automated ultrasound scanning - one legitimately promising application ready very soon. I’ve written about this work (ARTHUR/DIANA) for @RheumNow last year - check it out: https://t.co/Zq4ywEjspi https://t.co/3RYCVunE3a

• Will the Robots Save Ultrasound? | RheumNow
• https://x.com/drdavidliew/status/1982808768715899132/photo/1

#0852 LEVI-04, a novel p75NTR-Fc fusion protein, significantly reduces MRI bone marrow lesions in knee #OA 🦵📉 Phase II RCT (n=518): dose-dependent BML reduction (p<0.001) + correlated improvement in pain & function. Promising structure-modifying OA therapy @RheumNow #ACR25 https://t.co/huA8OaFGSd

• https://x.com/DrMiniDey/status/1982810011932975609/photo/1

@JYazdanyMD in the #ACR25 Great AI Debate details out three key risks of AI in rheumatology: - bias at scale - erosion of skills - data regulatory issues (for what it’s worth, amongst all the potential upside, I think it’s very real. It’s up to us to make it better) @RheumNow https://t.co/FyNes40Z7q

• https://x.com/drdavidliew/status/1982810038570803566/photo/1

In this ph2 trial of LEVI-04 for knee #osteoarthritis, At wk 20, LEVI-04 ⬇️ bone marrow lesions (BML), greater ⬇️ in BML area even w/ higher KL grades Promising treatment. #ACR25 @RheumNow Abs0852 #ACRBest https://t.co/MrmLPlFiDs

• https://x.com/RHEUMarampa/status/1982810691640680909/photo/1
• https://x.com/RHEUMarampa/status/1982810691640680909/photo/1
• https://x.com/RHEUMarampa/status/1982810691640680909/photo/1
• https://x.com/RHEUMarampa/status/1982810691640680909/photo/1